GlassScriptPhysician profile
William B Cundiff
NPI 1992969604
$11,118.51
in general payments reported to CMS, 2019-2025
36 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $547 · 2021: $146 · 2022: $399 · 2023: $7,633 · 2024: $738 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,174 · Food and Beverage: $1,530 · Travel and Lodging: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,174.14 |
| Food and Beverage | $1,529.97 |
| Travel and Lodging | $1,175.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,380.90 | 2022-2023 | Da Vinci Surgical System, Ion |
| Insmed, INC. | $535.50 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $374.13 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $302.70 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.34 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $228.62 | 2019-2024 | Dupixent |
| Sunovion Pharmaceuticals INC. | $208.65 | 2019 | |
| Grifols USA, LLC | $181.09 | 2019-2023 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $170.57 | 2019-2025 | Opsumit, Uptravi |
| Astellas Pharma US INC | $154.16 | 2019-2023 | Cresemba |
| Genzyme Corporation | $153.24 | 2024-2025 | |
| Genentech USA, INC. | $144.08 | 2019-2022 | |
| Pulmonx Corporation | $107.45 | 2022-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $99.27 | 2019-2022 | |
| Mylan Specialty L.P. | $84.90 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.88 | 2024-2025 | Winrevair, Zerbaxa, Dificid |
| Csl Behring | $61.73 | 2020-2024 | Kcentra |
| Bayer Healthcare Pharmaceuticals INC. | $52.39 | 2019-2022 | |
| Amgen INC. | $52.17 | 2024-2025 | Tezspire, Tavneos |
| Mayne Pharma Commercial LLC | $50.71 | 2019-2020 | |
| Philips North America LLC | $48.73 | 2019-2023 | |
| Shire North American Group INC | $37.88 | 2019 | |
| Galvanize Therapeutics, INC | $36.43 | 2024 | Aliya System |
| Baxter Healthcare | $35.46 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Tactile Systems Technology INC | $32.75 | 2025 | Nimbl, Flexitouch Plus |
| Boston Scientific Corporation | $32.74 | 2024 | Ekosonic |
| Viatris Specialty LLC | $31.85 | 2025 | Yupelri |
| Pfizer INC. | $28.35 | 2019 | |
| Abbvie INC. | $27.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.66 | 2024 | Aralast |
| Novartis Pharmaceuticals Corporation | $19.76 | 2019 | |
| Siemens Medical Solutions USA, INC. | $18.65 | 2024 | Cios Spin |
| Chiesi USA, INC. | $17.32 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $14.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cundiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.